We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Early Days, but HER2-positive Cancer Vaccine Shows Promise

News   Oct 01, 2018 | Original story from the American Association for Cancer Research

 
Early Days, but HER2-positive Cancer Vaccine Shows Promise

Dendritic cells: These antigen presenting cells scour the environment, picking up potentially dangerous particles. As part of this process, dendritic cells capture virions in their membranous folds. Image credit: Donald Bliss, National Library of Medicine. Source: Sriram Subramaniam, National Cancer Institute

 
 
 

RELATED ARTICLES

Compound Kills Chemotherapy-resistant Cancer Cells

News

Study reports the discovery of a compound that is capable of killing chemotherapy-resistant glioblastoma-initiating cells (GICs), raising hopes of producing drugs capable of eradicating refractory tumors with low toxicity.

READ MORE

Creatine Fuels T Cells’ Fight Against Cancer

News

Creatine serves as a molecular battery for immune cells by storing and distributing energy to fuel their fight against cancer, according to a new study.

READ MORE

Bioactive Agents Improve Synthetic Bone Substitutes

News

Synthetic bone substitutes are promising materials for bone defect repair, but their efficacy can be substantially improved by bioactive agents such as growth factors. In a new study, researchers have modified beta-tricalcium phosphate (β-TCP) with increasing quantities of bone morphogenetic protein 2 (BMP-2) derived from E. coli and shown improved bone healing.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE